Introduction: Chronic liver disease/cirrhosis (CLD) in individuals produces a variety of symptoms which in turn lead to a negative impact on health-related quality of life (HRQOL). However, no such work has been carried out in Pakistan. The general aim of this study was to evaluate the magnitude of poor HRQOL and to assess factors related with HRQOL in patients with CLD. Method: A cross-sectional study was conducted at the Gastroenterology Clinics of Aga Khan University Hospital. All adult patients diagnosed to have cirrhosis were invited to participate. In this study, Chronic Liver Disease Questionnaire (CLDQ) was used to assess HRQOL of these patients. Patients were categorized into 2 groups based on CLDQ score; <5 as poor and ≥5 as good score for determination of the frequency of poor HRQOL. CLDQ score was used as an outcome measure to determine the factors related with HRQOL. Result: Two-hundred and seventy-three participants were recruited; 155 (57%) were males. Mean age of participants was 49 years (SD ± 11 years). In this study, the most common cause for cirrhosis was viral infection 247 (91.5%). Mean Child Turcot Pugh (CTP) score was 8 ± 1.85 and the mean model for end stage liver disease (MELD) score was 12.6 ± 6.8. Two-hundred and nine patients (76.6%) had CTP B or C class. Poor HRQOL was seen in 187 (69%) Patients with spontaneous bacterial peritonitis, creatinine >1.5 mg/dL, hepatoma, coexisting malignancy, or paracentesis of <5 L were excluded. Demographics, etiology, and laboratory parameters along with the amount of LVP and the dose of albumin received were noted. Moreover, serum creatinine and serum sodium at baseline and 1 week post paracentesis were recorded. Result: Two-hundred and fourteen patients with cirrhosis underwent LVP during the study period. Among them, 141 met the inclusion criteria and were included for analysis. We found that 110 patients received 25 g of i.v. albumin while 31 received 50 g of IV albumin after LVP. Mean age in both these groups were 54 ± 11 and 53 ± 10 years, respectively. Hepatitis C was the predominant etiology which was found in 70% and 55% in 25 g and 50 g albumin group, respectively. More than 70% patients in both groups belonged to Child Turcot Pugh Class C. Mean ascitic fluid removed was 6.7 L in 25 g albumin group while 8.5 L in 50 g albumin group. Serum creatinine at baseline and 1 week post-LVP was 1.04 ± 0.02 and 1.07 ± 0.03 in the 25 g albumin group while 1.12 ± 0.04 and 1.41 ± 0.17 in 50 g albumin, respectively (P = 0.35). Similarly, serum sodium at baseline and 1 week post-LVP was 130.44 ± 3.5 and 129.62 ± 4.1 in the low-dose albumin group, while 129.62 ± 5.6 and 128.7 ± 6.0 in 50 g albumin (P = 0.14).
Conclusion:
We conclude that 25 g of 25% i.v. albumin may be as effective as 50 g in preventing renal impairment after LVP in cirrhosis. The results of this study need further validation in a large prospective cohort.
